U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H18ClNO2
Molecular Weight 255.741
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROXYBUPROPION, (±)-

SMILES

CC(NC(C)(C)CO)C(=O)C1=CC(Cl)=CC=C1

InChI

InChIKey=AKOAEVOSDHIVFX-UHFFFAOYSA-N
InChI=1S/C13H18ClNO2/c1-9(15-13(2,3)8-16)12(17)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C13H18ClNO2
Molecular Weight 255.741
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Bupropion is an atypical antidepressant that also has usefulness as a smoking-cessation aid. Because hydroxybupropion, a major metabolite of bupropion, is believed to contribute to its antidepressant activity, this metabolite may also contribute to the smoking-cessation properties of bupropion. Compared to bupropion hydroxybupropion inhibit norepinephrine (NE) uptake with similar potency. The effects of bupropion and enantiomers of hydroxybupropion on human nAChR subtypes indicate that the (2S,3S) isomer is more potent than the (2S,3R) isomer or racemic bupropion as an antagonist of alpha(4)beta(2) subtypes of nicotinic acetylcholine receptor (nAChR). In addition, both isomers of hydroxybupropion possess weaker antagonist activity to the alpha3/beta4 and alpha4/beta4 subtypes of nAChR.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rat. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q01959
Gene ID: 6531.0
Gene Symbol: SLC6A3
Target Organism: Homo sapiens (Human)
790.0 nM [IC50]
Target ID: P23975
Gene ID: 6530.0
Gene Symbol: SLC6A2
Target Organism: Homo sapiens (Human)
3.3 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.
2004 Sep
Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach.
2009 Feb
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion.
2012 Dec
Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.
2016 Apr 1
Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations.
2016 May
Design of experiment assisted concurrent enantioseparation of bupropion and hydroxybupropion by high-performance thin-layer chromatography.
2017 Feb
Patents

Patents

Sample Use Guides

Male and female Hairless IAF and Hartley guinea pigs: For i.v. bolus experiments, a dose of 1 mg/kg for both bupropion (BUP) and hydroxybupropion (BUPOH) were infused over a period of 30 s. For transdermal delivery, the developed TTS patches (two patches, 14.5 cm2 diffusional area) were applied to the dorsal region of the hairless guinea pigs. Blood samples were obtained for 48 h while patches were on the animal, and for another 48 h after patches were removed. Blood samples were obtained for 72 h following intravenous administration
Route of Administration: Intravenous
Bupropion analogs were evaluated in neurotransmitter uptake assays using synaptosomes prepared from rat brain (adult male Sprague-Dawley rats weighing 250g). Because no significant differences between rat and human synaptosomes were observed in studies of monoamine uptake data obtained using rat tissue should predict the behavior of these compounds at the corresponding human transporter. Bupropion is a relatively weak inhibitor of DA uptake with an IC50 of 550 nM, and it is even less potent as an inhibitor of NE reuptake. Compared with bupropion, its racemic hydroxyl metabolite produces equal inhibition of NE reuptake and much weaker inhibition of DA uptake. The (2S,3S isomer is the active form ), whereas the(2S,3R) isomer shows no significant inhibition of either DA or NE uptake. Compared with bupropion, (2S,3S)-hydroxybupropion produce similar or stronger inhibition of DA and NE uptake, respectively.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:58:24 GMT 2023
Edited
by admin
on Sat Dec 16 09:58:24 GMT 2023
Record UNII
V94F513635
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROXYBUPROPION, (±)-
Common Name English
6-HYDROXYBUPROPION
Common Name English
BW-306U
Code English
1-PROPANONE, 1-(3-CHLOROPHENYL)-2-((2-HYDROXY-1,1-DIMETHYLETHYL)AMINO)-
Systematic Name English
Code System Code Type Description
PUBCHEM
446
Created by admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
PRIMARY
EPA CompTox
DTXSID101002894
Created by admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
PRIMARY
WIKIPEDIA
HYDROXYBUPROPION
Created by admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
PRIMARY
CAS
82793-84-8
Created by admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
SUPERSEDED
FDA UNII
V94F513635
Created by admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
PRIMARY
CAS
92264-81-8
Created by admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
PRIMARY
CAS
357399-43-0
Created by admin on Sat Dec 16 09:58:24 GMT 2023 , Edited by admin on Sat Dec 16 09:58:24 GMT 2023
ALTERNATIVE
Related Record Type Details
PARENT -> METABOLITE